Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5929241 | American Heart Journal | 2011 | 11 Pages |
Abstract
In the overall target population, CCM did not improve VAT (the primary end point) but did improve pVo2 and MLWHFQ. Cardiac contractility modulation did not have an adverse affect on hospitalizations or mortality within the prespecified boundaries. Further study is required to clarify the role of CCM as a treatment for medically refractory heart failure.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Alan MD, Koonlawee MD, Kent MD, Steven MD, Suresh MD, Nirav MD, Owen MD, Stanislav MD, Marc MD, Peter MD, Kenneth MD, Robert MD, Michael PhD, Richard P. PhD, Rochelle PhD, Sidney MD, Yuval PhD, Daniel MD PhD, William T. MD,